A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

NCT00000798 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: HIV-1 Peptide Vaccine, Microparticulate Monovalent

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]